CORRECTION article

Front. Cell Dev. Biol., 25 June 2025

Sec. Cancer Cell Biology

Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1646699

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

  • 1. Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

  • 2. Department of Urology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

  • 3. Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, China

  • 4. Department of Radiotherapy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

  • 5. Department of Urology, The Fourth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

  • 6. First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China

  • 7. Department of Urology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

In the published article, there was an error in the legend for Figure 3E. Due to an oversight, the IC50 value for LNCaP-NC was incorrectly reported as:

FIGURE 3

“LNCaP-NC: 21.03 µM, 95% CI: 19.62–22.36.”

The corrected legend appears below.

“LNCaP-NC: 51.15 µM, 95% CI: 47.92–54.33.”

The authors apologize for this error and confirm that it does not affect the scientific conclusions of the article. The original article has been updated accordingly.

In the published article, there was an error in Figure 3E as presented. The visualization results for Figure 3E were correctly submitted and approved during the first round of revisions. However, due to an oversight on our part, this figure was inadvertently omitted in the second revised version. The corrected Figure 3E and its accompanying caption—Figure 3 ELOVL2 inhibition suppresses growth and restores enzalutamide sensitivity in resistant PCa cells—are provided below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

ELOVL2, enzalutamide resistance, androgen receptor, prostate cancer, CRPC

Citation

Cen J, Guo J, Zeng X, Song X, Ge S, Chen M, Li Q, Yu Y, Lv D and Zhao S (2025) Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer. Front. Cell Dev. Biol. 13:1646699. doi: 10.3389/fcell.2025.1646699

Received

13 June 2025

Accepted

16 June 2025

Published

25 June 2025

Volume

13 - 2025

Edited and reviewed by

Sehbanul Islam, University of Pennsylvania, United States

Updates

Copyright

*Correspondence: Yuzhong Yu, ; Daojun Lv, ; Shanchao Zhao,

† These authors have contributed equally to this work contribute to this work and share the first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics